Protara Therapeutics, Inc.

Protara Therapeutics, Inc.

TARA·NASDAQ

$4.22

-1.2%
HealthcareBiotechnology

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

At a Glance

Live Snapshot
Market Cap$162.85M
EPS-1.3400
P/E Ratio-3.15
Earnings Date07/30/2026

tara

Deferred Revenue (Non-Current)

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Protara Therapeutics, Inc.

Protara Therapeutics, Inc. Competitors Analysis of Deferred Revenue (Non-Current)

TARA · NASDAQ
CompanyDeferred Revenue (Non-Current)
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
IVVD logo
Invivyd, Inc.
NASDAQ:IVVD
0.00
N/AN/AN/A
0.00
N/AN/AN/A
CDXS logo
Codexis, Inc.
NASDAQ:CDXS
360.00K
-17.5%-37.4%-10.3%
OABI logo
OmniAb, Inc.
NASDAQ:OABI
0.00
N/AN/AN/A
5.87M
N/A-48.8%2.8%
Protara Therapeutics, Inc.

Protara Therapeutics, Inc. Fair Value Envelope

TARA · NASDAQ

Our analysis suggests that TARA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.22, this represents a potential HIDDEN relative to our calculated worth for Protara Therapeutics, Inc..

Intrinsic Value
Current Price: $4.22